About this trial
Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care. The primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient's susceptibility to experience therapy failure and/or adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy. The cases will be supplemented with information on additional Parameters reported in the literature to affect efficacy or safety of the respective drug.
Eligibility criteria
Qualifiers
New medication with known PGx association (preemptive)
Current medication with observation of adverse drug reactions probably linked to drugs with known PGx association (reactive)
Current medication with observation of therapy failure probably linked to drugs with known PGx association (reactive)
Current and/or new medication and a family history of adverse drug reactions/therapy failure probably linked to drugs with known PGx association
Disqualifiers
Insufficient German knowledge
Not able to personally visit to the study pharmacy
Trial design
Treatments tested in this trial
- Buccal swab
- EDTA Blood sample (4.9mL)
- Serum sample (7.5mL)
- communication of test results
- unstructured interview
Treatment groups
Sponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Toppharm Apotheke Hersberger, Spalenberg 41, CH-4051 Basel
Collaborator
Universitätskinderspital Zürich, Lenggstrasse 30, 8008 Zürich
Collaborator
Institut für Spitalpharmazie, Solothurner Spitäler AG, Baslerstrasse 150, 4600 Olten
Collaborator